Cantor Fitzgerald maintains an Overweight rating on Vaxcyte, with Gould explaining the firm's position amid ACIP meeting effects.

1 report, 0 independent Updated Jul 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Cantor Fitzgerald Gould

Keep exploring

Part of

PGIM Jennison Health Sciences Fund held Vaxcyte stock in Q1 2025 and currently prefers AI stocks for higher returns. All 1 developments

The entities involved

Cantor Fitzgerald
American financial services company
- TD Cowen reaffirmed a buy rating while Cantor Fitzgerald downgraded monday.com Ltd. on October 6, 2026.03:57
- Cantor Fitzgerald increased its price objective on Intuitive Machines, with MarketBeat providing average ratings and target prices.Wed 18:04
Gould
- AMA established a CPT code for CPS assessment, while Sensydia named Anthony Arnold as CEO and Gould to lead commercialization.Tue 14:30

Related events

Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.Oct 8
Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.Jun 10
Cantor Fitzgerald set an overweight rating for Enovix Corporation on October 8, 2026.Oct 8
Nyxoah SA was listed on the Nasdaq exchange, and Cantor Fitzgerald reiterated an overweight rating on the company.Jun 28
Multiple financial firms, including Cantor Fitzgerald and William Blair, issued rating updates and price targets for various stocks on August 10, 2026.Aug 10

Coverage

Newest first; wire copies grouped

Jul 2Unknown outlet